Third Panel’s The Charm For Watchman? More Delays For Boston Sci’s Stroke Device

FDA has requested that a PMA for Boston Scientific’s Watchman left atrial appendage closure device for stroke-prevention be subject to another advisory panel meeting -- the third since 2009 -- which will delay the launch to, at earliest, the first half of 2015, the company says.

More from Clinical Trials

More from R&D